All In Biotech

Drug Trial Radar · NCT05959304

Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.

A Prospective, Multi-center, Open-label, Phase IV Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Diabetic Macular Edema (DME).

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Dec 11, 2024

Primary completion

Nov 17, 2025

Study completion Nov 17, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab. This study is being conducted as part of the post-marketing regulatory commitment to the Indian Health authority.

Conditions

  • Diabetic Macular Edema

Interventions

  • brolucizumabDrug

    There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and characteristics of treatment-emergent adverse events during the 40 weeks of treatment with Brolucizumab.Time frame: 40 weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Coimbatore, India

  • Novartis Investigative Site

    Kolkata, India

  • Novartis Investigative Site

    New Delhi, India

  • Novartis Investigative Site

    Ahmedabad, Gujarat, India

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    Kochi, Kerala, India

  • Novartis Investigative Site

    Chennai, Tamil Nadu, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.